Mechanistic Study of Duloxetine in Breast Cancer Patients With Chronic Pain

PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

October 30, 2013

Primary Completion Date

June 28, 2019

Study Completion Date

June 28, 2019

Conditions
Pain
Interventions
DRUG

Duloxetine

Subjects will receive 30 mg duloxetine orally for 7 days, then 60 mg duloxetine orally for 28 days, then 30 mg duloxetine orally x 14 days.

Trial Locations (2)

48103

University of Michigan Rogel Cancer Center, Ann Arbor

84112

Huntsman Cancer Institute, Salt Lake City

All Listed Sponsors
collaborator

American Cancer Society, Inc.

OTHER

lead

University of Michigan Rogel Cancer Center

OTHER

NCT01912612 - Mechanistic Study of Duloxetine in Breast Cancer Patients With Chronic Pain | Biotech Hunter | Biotech Hunter